CSL Behring Expands Zemaira Product Line with New Vial Sizes

CSL Behring, a leading biotherapeutics company, has announced the availability of larger vial sizes for their alpha1-proteinase inhibitor (A1-PI) therapy, Zemaira. Previously, Zemaira was only offered in a 1g vial size, but now patients can benefit from 4g and 5g vials.

Zemaira is specifically indicated for adults with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema. The treatment is administered as chronic augmentation and maintenance therapy. The dosing regimen for Zemaira is weight-based, so the introduction of larger vial sizes will reduce the number of reconstituted vials needed per dose.

The new vial sizes contain approximately 4000mg and 5000mg of functionally active A1-PI. The amount of functional A1-PI is clearly labeled on both the vial and the carton, ensuring accurate dosing for healthcare professionals.

The expansion of the Zemaira product line reflects CSL Behring’s ongoing commitment to the alpha-1 community. Shannen Silvestrini, Director of Zemaira Marketing at CSL Behring, expressed the company’s dedication to addressing the unmet needs of patients. By offering larger vial sizes, CSL Behring aims to provide a more convenient and efficient treatment option for healthcare professionals when preparing Zemaira for their patients.

Zemaira has been a trusted therapy within the Alpha-1 community for the past 20 years. With the introduction of larger vial sizes, patients can now benefit from a more streamlined treatment approach. This development showcases CSL Behring’s commitment to continuously improving their therapies and patient programs.

In conclusion, CSL Behring’s expansion of the Zemaira product line to include 4g and 5g vial sizes brings added convenience to healthcare professionals and patients. This development ensures accurate dosing and reflects the company’s dedication to meeting the needs of the alpha-1 community.

FAQ Section:

1. What is Zemaira?
Zemaira is a therapy developed by CSL Behring, a biotherapeutics company. It is specifically indicated for adults with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema.

2. What is the dosing regimen for Zemaira?
The dosing regimen for Zemaira is weight-based. It is administered as chronic augmentation and maintenance therapy.

3. What are the new vial sizes available for Zemaira?
CSL Behring has announced the availability of larger vial sizes for Zemaira. Previously, it was only offered in a 1g vial size, but now patients can benefit from 4g and 5g vials.

4. How does the introduction of larger vial sizes benefit patients?
The introduction of larger vial sizes reduces the number of reconstituted vials needed per dose, providing a more convenient and efficient treatment option for patients.

5. How is the accurate dosing ensured for healthcare professionals?
The amount of functionally active alpha1-proteinase inhibitor (A1-PI) is clearly labeled on both the vial and the carton, ensuring accurate dosing for healthcare professionals.

6. What does the expansion of the Zemaira product line reflect?
The expansion of the Zemaira product line reflects CSL Behring’s ongoing commitment to the alpha-1 community and their dedication to addressing the unmet needs of patients.

7. How long has Zemaira been a trusted therapy?
Zemaira has been a trusted therapy within the Alpha-1 community for the past 20 years.

Definitions:
– Alpha1-proteinase inhibitor deficiency: A genetic disorder in which the body does not produce enough alpha1-antitrypsin (A1AT) protein, resulting in increased risk of lung and liver diseases.
– Emphysema: A long-term, progressive lung disease that primarily affects the air sacs in the lungs, making breathing difficult.

Suggested Related Links:
– CSL Behring Official Website

Leave a Comment

. . . . .

bbj fgl ykw mlf yvj vbp twx yar sar hyr woj rrk ruw wil aky pmg ibq lie hwe kom hjn vne cxr ner mjf ayb vsn elx hdl ltj fhi xah ghr brj eze yjh clb eor ezl rkb ahv